Abzena PLC Partner Halozyme to present poster at AACR
03 March 2017 - 6:00PM
RNS Non-Regulatory
TIDMABZA
Abzena PLC
03 March 2017
Abzena plc
Partner Halozyme to present poster at AACR
Cambridge, UK, 3 March 2017 - Abzena plc (AIM: ABZA, 'Abzena' or
the 'Group'), the life sciences group providing services and
technologies to enable the development and manufacture of
biopharmaceutical products, notes that partner Halozyme
Therapeutics' ("Halozyme") has published an abstract for its poster
presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2017 on 2 April 2017.
The abstract outlines the significant preclinical anti-tumour
activity of Halozyme's HTI-1511 antibody drug conjugate (ADC),
which uses Abzena's novel, site specific ThioBridge(TM) linker
technology. This will be presented in the poster 'HTI-1511, a novel
anti-EGFR-ADC, overcomes mutation resistance and demonstrates
significant activity against multiple tumor types in preclinical
studies'. The poster is jointly authored by scientists from Abzena,
Halozyme and Champions Oncology Inc.
The abstract can be viewed online at: http://bit.ly/2mxFoTH The
AACR Annual Meeting will be held at the Walter E. Washington
Convention Center in Washington, D.C. from April 1 to April 5.
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief +44 1223 903
Financial Officer 498
Instinctif Partners +44 20 7457
Melanie Toyne-Sewell / Rozi 2020
Morris/ Alex Shaw abzena@instinctif.com
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKBDNFBKDONK
(END) Dow Jones Newswires
March 03, 2017 02:00 ET (07:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024